Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors
The 3,5-dimethylisoxazole motif has become a useful and popular acetyl-lysine mimic employed in isoxazole-containing bromodomain and extra-terminal (BET) inhibitors but may introduce the potential for bioactivations into toxic reactive metabolites. As a test, we coupled deep neural models for quinon...
Main Authors: | Noah R. Flynn, Michael D. Ward, Mary A. Schleiff, Corentine M. C. Laurin, Rohit Farmer, Stuart J. Conway, Gunnar Boysen, S. Joshua Swamidass, Grover P. Miller |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Metabolites |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-1989/11/6/390 |
Similar Items
-
Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers
by: Martin V. Nguyen, et al.
Published: (2020-02-01) -
Development of a Novel Positron Emission Tomography (PET) Radiotracer Targeting Bromodomain and Extra-Terminal Domain (BET) Family Proteins
by: Ping Bai, et al.
Published: (2020-08-01) -
Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
by: Archit Trivedi, et al.
Published: (2020-03-01) -
Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins
by: Jiacheng Lai, et al.
Published: (2021-09-01) -
Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases
by: Dayu Wu, et al.
Published: (2022-08-01)